BPA Biosante Pharmaceuticals

Standard & Poor�s announced today that it has commenced Factual Stock Report coverage on BioSante Pharmaceuticals, Inc. BioSante Pharmaceuticals, Inc. (AMEX:BPA) is a development stage biopharmaceutical company that is developing a pipeline of hormone therapy products to treat men and women. It is also developing its proprietary calcium phosphate nanotechnology, or CaP, primarily for vaccine adjuvants or immune system boosters and drug delivery systems. The company's hormone therapy products address a variety of hormone therapies for symptoms that affect both men and women. Symptoms addressed by these therapies include impotence, lack of sex drive, muscle weakness and osteoporosis in men and menopausal symptoms in women including hot flashes, vaginal atrophy, decreased libido and osteoporosis. The products are gel formulations of testosterone, estradiol, a combination of estradiol and testosterone and a combination of estradiol and progestogen. Two exciting near term products in development by BioSante include LibiGel� for the treatment of female sexual dysfunction (entering Phase III) and Bio-E-Gel� for the treatment of hot flashes in women, which has completed clinical development and regarding which an NDA has been submitted to FDA in February 2006. These gel products are designed to be quickly absorbed through the skin after application on an upper arm, delivering the hormone to the bloodstream evenly in a fast drying, non-invasive, painless manner. The gels are formulated to be applied once per day and to be absorbed into the skin without a trace of residue. This report will also be accessible on an ongoing basis to a wide audience of the investment community ---- scores of buy-side institutions and sell-side firms that utilize S&P research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. About Standard & Poor�s Factual Stock Reports This S&P service provides factual research coverage enabling companies to reach a wide investor audience of Buy and Sell-side investors, helping them understand the fundamentals and business prospects. Many of these companies are not widely covered by Wall Street analysts. Currently profiling over 1,000 issuers, S&P Factual Stock Reports increase market awareness for companies in the investment community with insightful commentary and key statistics/information. Updated weekly with the latest pricing, trading volume and other data, the reports include recent developments, an income statement analysis and financial review, key operating information, performance charts, business summary, fundamental data, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, and news. Because coverage of these reports is sponsored by the issuer, S&P does not offer investment opinions concerning the advisability of investing in these stocks. Standard & Poor�s Factual Stock Reports are produced separately from any other analytic activity of Standard & Poor�s. Standard & Poor�s Factual Report research has no access to non-public information received by other units of Standard & Poor�s. Standard & Poor�s does not trade on its own account. Note: All U.S. and Canadian Companies listed on a National Exchange (not covered by S&P�s STARS research) are eligible to obtain this coverage. About Standard & Poor's Standard & Poor's, a division of The McGraw-Hill Companies (NYSE:MHP), is the world�s foremost provider of independent credit ratings, indices, risk evaluation, investment research, data and valuations. With approximately 6,300 employees located in 20 countries and markets, Standard & Poor's is an essential part of the world�s financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions. For more information, visit http://www.standardandpoors.com. Standard & Poor's announced today that it has commenced Factual Stock Report coverage on BioSante Pharmaceuticals, Inc. BioSante Pharmaceuticals, Inc. (AMEX:BPA) is a development stage biopharmaceutical company that is developing a pipeline of hormone therapy products to treat men and women. It is also developing its proprietary calcium phosphate nanotechnology, or CaP, primarily for vaccine adjuvants or immune system boosters and drug delivery systems. The company's hormone therapy products address a variety of hormone therapies for symptoms that affect both men and women. Symptoms addressed by these therapies include impotence, lack of sex drive, muscle weakness and osteoporosis in men and menopausal symptoms in women including hot flashes, vaginal atrophy, decreased libido and osteoporosis. The products are gel formulations of testosterone, estradiol, a combination of estradiol and testosterone and a combination of estradiol and progestogen. Two exciting near term products in development by BioSante include LibiGel(R) for the treatment of female sexual dysfunction (entering Phase III) and Bio-E-Gel(R) for the treatment of hot flashes in women, which has completed clinical development and regarding which an NDA has been submitted to FDA in February 2006. These gel products are designed to be quickly absorbed through the skin after application on an upper arm, delivering the hormone to the bloodstream evenly in a fast drying, non-invasive, painless manner. The gels are formulated to be applied once per day and to be absorbed into the skin without a trace of residue. This report will also be accessible on an ongoing basis to a wide audience of the investment community ---- scores of buy-side institutions and sell-side firms that utilize S&P research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. About Standard & Poor's Factual Stock Reports This S&P service provides factual research coverage enabling companies to reach a wide investor audience of Buy and Sell-side investors, helping them understand the fundamentals and business prospects. Many of these companies are not widely covered by Wall Street analysts. Currently profiling over 1,000 issuers, S&P Factual Stock Reports increase market awareness for companies in the investment community with insightful commentary and key statistics/information. Updated weekly with the latest pricing, trading volume and other data, the reports include recent developments, an income statement analysis and financial review, key operating information, performance charts, business summary, fundamental data, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, and news. Because coverage of these reports is sponsored by the issuer, S&P does not offer investment opinions concerning the advisability of investing in these stocks. Standard & Poor's Factual Stock Reports are produced separately from any other analytic activity of Standard & Poor's. Standard & Poor's Factual Report research has no access to non-public information received by other units of Standard & Poor's. Standard & Poor's does not trade on its own account. Note: All U.S. and Canadian Companies listed on a National Exchange (not covered by S&P's STARS research) are eligible to obtain this coverage. About Standard & Poor's Standard & Poor's, a division of The McGraw-Hill Companies (NYSE:MHP), is the world's foremost provider of independent credit ratings, indices, risk evaluation, investment research, data and valuations. With approximately 6,300 employees located in 20 countries and markets, Standard & Poor's is an essential part of the world's financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions. For more information, visit http://www.standardandpoors.com.